No Data
No Data
Inozyme Gets Fast Track Status for Candidate for Rare Calcification Condition
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright analyst Edward White maintains $Inozyme Pharma(INZY.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 28.1% an
Buy Rating Affirmed for Inozyme Pharma Amid Promising Drug Developments and Strong Revenue Projections
Express News | Inozyme Pharma Shares Are Trading Higher After the Company Announced That the FDA Granted Fast Track Designation to INZ-701 for the Treatment of ABCC6 Deficiency
Express News | Inozyme Pharma Inc - Targets Pivotal Study for Inz-701 by Year-End
Express News | Inozyme Pharma Announces FDA Fast Track Designation for Inz-701 in Abcc6 Deficiency
No Data